The hormonal profile of norethindrone acetate: Rationale for add-back therapy with gonadotropin-releasing hormone agonists in women with endometriosis

Reproductive Sciences

Volumn 19, Issue 6, 2012, Pages 563-571

  Chwalisz, Kristof ^a   Surrey, Eric ^b   Stanczyk, Frank Z ^c  

^a ABBOTT LABORATORIES   (United States)

^b National Foundation for Fertility Research   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

endometriosis; GnRH agonist; norethindrone acetate

Indexed keywords

ESTROGEN; GONADORELIN AGONIST; HIGH DENSITY LIPOPROTEIN; NORETHISTERONE ACETATE; PROGESTERONE;

BONE ATROPHY; BONE DENSITY; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG INDICATION; ENDOMETRIOSIS; ESTROGEN ACTIVITY; HORMONAL THERAPY; HOT FLUSH; HUMAN; PELVIS PAIN SYNDROME; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; VASOMOTOR DISORDER;

BONE DENSITY; ENDOMETRIOSIS; ESTROGENS; FEMALE; GONADOTROPIN-RELEASING HORMONE; HOT FLASHES; HUMANS; LIPOPROTEINS, HDL; NORETHINDRONE; OSTEOPOROSIS; PELVIC PAIN; PROGESTERONE;

EID: 84862837705     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719112438061     Document Type: Review

References (83)

1. European Society of Human Reproduction and Embryology. ESHRE guideline for the diagnosis and treatment of endometriosis. 2010; http://guidelines. endometriosis.org/index.html. Accessed July 27, 2010.
2. Gambone JC, Mittman BS, Munro MG, Scialli AR, Winkel CA. Consensus statement for the management of chronic pelvic pain and endometriosis: proceedings of an expert-panel consensus process. Fertil Steril. 2002 ; 78 (5). 961-972 (Pubitemid 35292495)
3. Olive DL. Gonadotropin-releasing hormone agonists for endometriosis. N Engl J Med. 2008 ; 359 (11). 1136-1142
4. Surrey ES. Gonadotropin-releasing hormone agonist and add-back therapy: what do the data show?. Curr Opin Obstet Gynecol. 2010 ; 22 (4). 283-288
5. Agorastos T, Vaitsi V, Paschopoulos M, et al. Prolonged use of gonadotropin-releasing hormone agonist and tibolone as add-back therapy for the treatment of endometrial hyperplasia. Maturitas. 2004 ; 48 (2). 125-132 (Pubitemid 38692575)
6. Olive DL. The role of add-back therapy in the United States. Drugs Today (Barc). 2005 ; 41 (suppl A). 23-26 (Pubitemid 41113620)
7. Surrey ES. The role of progestins in treating the pain of endometriosis. J Minim Invasive Gynecol. 2006 ; 13 (6). 528-534 (Pubitemid 44693481)
8. Surrey ES. Add-back therapy and gonadotropin-releasing hormone agonists in the treatment of patients with endometriosis: can a consensus be reached? Add-Back Consensus Working Group. Fertil Steril. 1999 ; 71 (3). 420-424 (Pubitemid 29094115)
9. Hornstein MD, Surrey ES, Weisberg GW, Casino LA. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group. Obstet Gynecol. 1998 ; 91 (1). 16-24 (Pubitemid 28042326)
10. Falcone T, Lebovic DI. Clinical management of endometriosis. Obstet Gynecol. 2011 ; 118 (3). 691-705
11. Mounsey AL, Wilgus A, Slawson DC. Diagnosis and management of endometriosis. Am Fam Physician. 2006 ; 74 (4). 594-600
12. ESHRE. ESHRE guideline for the diagnosis and treatment of endometriosis 2010; http://guidelines.endometriosis.org/index.html. Accessed July 27, 2010.
13. Fuldeore MJ, Marx SE, Chwalisz K, Smeeding JE, Brook RA. Add-back therapy use and its impact on LA persistence in patients with endometriosis. Curr Med Res Opin. 2010 ; 26 (3). 729-736
14. Stanczyk FZ Treatment of the Postmenopausal Woman: Basic and Clinical Aspects. 3 rd ed. Burlington, MA: Academic Press; 2007:779-798. Lobo RA, ed. Burlington, MA: Academic Press ; 2007: 779-798.
15. Wiegratz I, Kuhl H. Progestogen therapies: differences in clinical effects?. Trends Endocrinol Metab. 2004 ; 15 (6). 277-285 (Pubitemid 39044202)
16. Kenemans P, Speroff L. Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group. Maturitas. 2005 ; 51 (1). 21-28 (Pubitemid 40692595)
17. Albertazzi P, Bottazzi M, Steel SA. Bone mineral density and depot medroxyprogesterone acetate. Contraception. 2006 ; 73 (6). 577-583 (Pubitemid 43786283)
18. Meier C, Brauchli YB, Jick SS, Kraenzlin ME, Meier CR. Use of depot medroxyprogesterone acetate and fracture risk. J Clin Endocrinol Metab. 2010 ; 95 (11). 4909-4916
19. Schindler AE, Campagnoli C, Druckmann R, et al. Classification and pharmacology of progestins. Maturitas. 2003 ; 46 (suppl 1). S7 - S16
20. Back DJ, Breckenridge AM, Crawford FE, et al. Kinetics of norethindrone in women. I. Radioimmunoassay and concentrations during multiple dosing. Clin Pharmacol Ther. 1978 ; 24 (4). 439-447 (Pubitemid 9059907)
21. Back DJ, Breckenridge AM, Crawford FE, et al. Kinetics of norethindrone in women. II. Single-dose kinetics. Clin Pharmacol Ther. 1978 ; 24 (4). 448-453 (Pubitemid 9059908)
22. Stanczyk FZ, Roy S. Metabolism of levonorgestrel, norethindrone, and structurally related contraceptive steroids. Contraception. 1990 ; 42 (1). 67-96 (Pubitemid 20208813)
23. Kuhnz W, Heuner A, Humpel M, Seifert W, Michaelis K. In vivo conversion of norethisterone and norethisterone acetate to ethinyl etradiol in postmenopausal women. Contraception. 1997 ; 56 (6). 379-385 (Pubitemid 28079880)
24. Chu MC, Zhang X, Gentzschein E, Stanczyk FZ, Lobo RA. Formation of ethinyl estradiol in women during treatment with norethindrone acetate. J Clin Endocrinol Metab. 2007 ; 92 (6). 2205-2207 (Pubitemid 46997123)
25. Burkman RT, Fisher AC, Wan GJ, Barnowski CE, LaGuardia KD. Association between efficacy and body weight or body mass index for two low-dose oral contraceptives. Contraception. 2009 ; 79 (6). 424-427
26. Barbieri RL. Hormone treatment of endometriosis: the estrogen threshold hypothesis. Am J Obstet Gynecol. 1992 ; 166 (2). 740-745
27. Smith CL, O'Malley BW. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev. 2004 ; 25 (1). 45-71 (Pubitemid 38292038)
28. Smith CL, Nawaz Z, O'Malley BW. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol. 1997 ; 11 (6). 657-666 (Pubitemid 27225293)
29. Chwalisz K, Perez MC, Demanno D, Winkel C, Schubert G, Elger W. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr Rev. 2005 ; 26 (3). 423-438 (Pubitemid 40686652)
30. Ke HZ, Chen HK, Simmons HA, et al. Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model. Bone. 1997 ; 20 (1). 31-39 (Pubitemid 27046637)
31. Weiss SR, Ellman H, Dolker M. A randomized controlled trial of four doses of transdermal estradiol for preventing postmenopausal bone loss. Transdermal Estradiol Investigator Group. Obstet Gynecol. 1999 ; 94 (3). 330-336 (Pubitemid 29393064)
32. Genant HK, Lucas J, Weiss S, et al. Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab/Osteoporosis Study Group. Arch Intern Med. 1997 ; 157 (22). 2609-2615 (Pubitemid 27519981)
33. Mashchak CA, Lobo RA, Dozono-Takano R, et al. Comparison of pharmacodynamic properties of various estrogen formulations. Am J Obstet Gynecol. 1982 ; 144 (5). 511-518 (Pubitemid 12002825)
34. Prior JC. Progesterone as a bone-trophic hormone. Endocr Rev. 1990 ; 11 (2). 386-398 (Pubitemid 20182875)
35. Rickard DJ, Iwaniec UT, Evans G, et al. Bone growth and turnover in progesterone receptor knockout mice. Endocrinology. 2008 ; 149 (5). 2383-2390 (Pubitemid 351574494)
36. Wells G, Tugwell P, Shea B, et al. Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev. 2002 ; 23 (4). 529-539 (Pubitemid 34925647)
37. Gallagher JC, Kable WT, Goldgar D. Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen. Am J Med. 1991 ; 90 (2). 171-178
38. Thijssen JH. Long-term effects of progestins on bone quality and fractures. Gynecol Endocrinol. 2007 ; 23 (suppl 1). 45-52 (Pubitemid 47613713)
39. Kawano H, Sato T, Yamada T, et al. Suppressive function of androgen receptor in bone resorption. Proc Natl Acad Sci U S A. 2003 ; 100 (16). 9416-9421 (Pubitemid 37033943)
40. Soule SG, Conway G, Prelevic GM, Prentice M, Ginsburg J, Jacobs HS. Osteopenia as a feature of the androgen insensitivity syndrome. Clin Endocrinol (Oxf). 1995 ; 43 (6). 671-675 (Pubitemid 26015011)
41. Smith EP, Boyd J, Frank GR, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med. 1994 ; 331 (16). 1056-1061 (Pubitemid 24317698)
42. Abdalla HI, Hart DM, Lindsay R, Leggate I, Hooke A. Prevention of bone mineral loss in postmenopausal women by norethisterone. Obstet Gynecol. 1985 ; 66 (6). 789-792 (Pubitemid 16216248)
43. Moore RA. Livial: a review of clinical studies. Br J Obstet Gynaecol. 1999 ; 106 (suppl 19). 1-21 (Pubitemid 29118992)
44. Horowitz M, Wishart J, Need AG, Morris H, Philcox J, Nordin BE. Treatment of postmenopausal hyperparathyroidism with norethindrone. Effects on biochemistry and forearm mineral density. Arch Intern Med. 1987 ; 147 (4). 681-685 (Pubitemid 17063550)
45. Johansen JS, Jensen SB, Riis BJ, Christiansen C. Time-dependent variations in bone turnover parameters during 2 months' cyclic treatment with different doses of combined estrogen and progestogen in postmenopausal women. Metabolism. 1990 ; 39 (11). 1122-1126 (Pubitemid 20376340)
46. Eiken P, Kolthoff N, Nielsen SP. Effect of 10 years' hormone replacement therapy on bone mineral content in postmenopausal women. Bone. 1996 ; 19 (5 suppl). 191S - 193S (Pubitemid 26397222)
47. Pors Nielsen S, Barenholdt O, Hermansen F, Munk-Jensen N. Magnitude and pattern of skeletal response to long term continuous and cyclic sequential oestrogen/progestin treatment. Br J Obstet Gynaecol. 1994 ; 101 (4). 319-324 (Pubitemid 24196001)
48. Crosignani P, Olive D, Bergqvist A, Luciano A. Advances in the management of endometriosis: an update for clinicians. Hum Reprod Update. 2006 ; 12 (2). 179-189 (Pubitemid 43231450)
49. Crosignani PG, Luciano A, Ray A, Bergqvist A. Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Hum Reprod. 2006 ; 21 (1). 248-256 (Pubitemid 41794318)
50. Fernandez H, Lucas C, Hedon B, Meyer JL, Mayenga JM, Roux C. One year comparison between two add-back therapies in patients treated with a GnRH agonist for symptomatic endometriosis: a randomized double-blind trial. Hum Reprod. 2004 ; 19 (6). 1465-1471 (Pubitemid 38807725)
51. Roux C, Lucas C, Briot K, Kolta S, Fechtenbaum J, Fernandez H USA, Sponsor: Amer Soc Bone & Mineral Res ; 2005 :
52. Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril. 2001 ; 75 (6). 1065-1079 (Pubitemid 32522600)
53. Goodwin JW, Green SJ, Moinpour CM, et al. Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group Study 9626. J Clin Oncol. 2008 ; 26 (10). 1650-1656
54. Loprinzi CL, Michalak JC, Quella SK, et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med. 1994 ; 331 (6). 347-352 (Pubitemid 24233853)
55. Kuhl H. Mechanisms of sex steroids. Future developments. Maturitas. 2004 ; 47 (4). 285-291 (Pubitemid 38520114)
56. Fraser DI, Parsons A, Whitehead MI, Wordsworth J, Stuart G, Pryse-Davies J. The optimal dose of oral norethindrone acetate for addition to transdermal estradiol: a multicenter study. Fertil Steril. 1990 ; 53 (3). 460-468 (Pubitemid 20093608)
57. Princeton, NJ: Novo Nordisk ; 2006.
58. Clarke RB. Steroid receptors and proliferation in the human breast. Steroids. 2003 ; 68 (10-13). 789-794 (Pubitemid 37532401)
59. Soderqvist G, Isaksson E, von Schoultz B, Carlstrom K, Tani E, Skoog L. Proliferation of breast epithelial cells in healthy women during the menstrual cycle. Am J Obstet Gynecol. 1997 ; 176 (1 pt 1). 123-128 (Pubitemid 127780760)
60. Lundstrom E, Wilczek B, von Palffy Z, Soderqvist G, von Schoultz B. Mammographic breast density during hormone replacement therapy: differences according to treatment. Am J Obstet Gynecol. 1999 ; 181 (2). 348-352 (Pubitemid 29409912)
61. Conner P, Svane G, Azavedo E, et al. Mammographic breast density, hormones, and growth factors during continuous combined hormone therapy. Fertil Steril. 2004 ; 81 (6). 1617-1623 (Pubitemid 38749007)
62. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002 ; 288 (3). 321-333 (Pubitemid 34761611)
63. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003 ; 362 (9382). 419-427 (Pubitemid 36999703)
64. Chlebowski RT, Anderson GL, Gass M, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA. 2010 ; 304 (15). 1684-1692
65. Lyytinen H, Dyba T, Pukkala E, Ylikorkala O. Do the dose or route of administration of norethisterone acetate as a part of hormone therapy play a role in risk of breast cancer: national-wide case-control study from Finland. Int J Cancer. 2010 ; 127 (1). 185-189
66. Stuedal A, Ma H, Bjorndal H, Ursin G. Postmenopausal hormone therapy with estradiol and norethisterone acetate and mammographic density: findings from a cross-sectional study among Norwegian women. Climacteric. 2009 ; 12 (3). 248-258
67. SEER Cancer Statistics Review, 1975-2007. National Cancer Institute Web site. http://seer.cancer.gov/csr/1975-2007/. Accessed July 29, 2011.
68. Speroff L, Darney PD A Clinical Guide for Contraception. 4 th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005. Philadelphia, PA: Lippincott Williams & Wilkins ; 2005 :
69. Collaborative Group on Hormonal Factors in Breast Cancer. Contraception. 1996 ; 54 (3 suppl). 1S - 106S
70. Rosenberg L, Palmer JR, Clarke EA, Shapiro S. A case-control study of the risk of breast cancer in relation to oral contraceptive use. Am J Epidemiol. 1992 ; 136 (12). 1437-1444
71. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet. 1996 ; 347 (9017). 1713-1727
72. Plu-Bureau G, Le MG, Sitruk-Ware R, Thalabard JC, Mauvais-Jarvis P. Progestogen use and decreased risk of breast cancer in a cohort study of premenopausal women with benign breast disease. Br J Cancer. 1994 ; 70 (2). 270-277 (Pubitemid 24247148)
73. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007 ; 297 (13). 1465-1477 (Pubitemid 46556472)
74. Bernstein P, Pohost G. Progesterone, progestins, and the heart. Rev Cardiovasc Med. 2010 ; 11 (4). 228-236
75. Crews JK, Khalil RA. Antagonistic effects of 17 beta-estradiol, progesterone, and testosterone on Ca2+ entry mechanisms of coronary vasoconstriction. Arterioscler Thromb Vasc Biol. 1999 ; 19 (4). 1034-1040 (Pubitemid 29177353)
76. Earl PL, Sugiura W, Montefiori DC, et al. Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140. J Virol. 2001 ; 75 (2). 645-653 (Pubitemid 32037268)
77. Jiang CW, Sarrel PM, Lindsay DC, Poole-Wilson PA, Collins P. Progesterone induces endothelium-independent relaxation of rabbit coronary artery in vitro. Eur J Pharmacol. 1992 ; 211 (2). 163-167
78. Minshall RD, Pavcnik D, Browne DL, Hermsmeyer K. Nongenomic vasodilator action of progesterone on primate coronary arteries. J Appl Physiol. 2002 ; 92 (2). 701-708 (Pubitemid 34671040)
79. Pedersen SH, Pedersen NG, Dalsgaard T, Lund CO, Nilas L, Ottesen B. Different cerebrovascular effects of medroxyprogesterone acetate and norethisterone acetate in the New Zealand White rabbit. Climacteric. 2004 ; 7 (1). 12-22 (Pubitemid 38367159)
80. Rosano GM, Webb CM, Chierchia S, et al. Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women. J Am Coll Cardiol. 2000 ; 36 (7). 2154-2159
81. Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Fertil Steril. 2001 ; 75 (5). 898-915 (Pubitemid 32401667)
82. Kuhl H. Effects of progestogens on haemostasis. Maturitas. 1996 ; 24 (1-2). 1-19 (Pubitemid 26180099)
83. Herkert O, Kuhl H, Sandow J, Busse R, Schini-Kerth VB. Sex steroids used in hormonal treatment increase vascular procoagulant activity by inducing thrombin receptor (PAR-1) expression: role of the glucocorticoid receptor. Circulation. 2001 ; 104 (23). 2826-2831 (Pubitemid 33126658)